Research programme: skin disorder therapeutics - Celtic Pharma

Drug Profile

Research programme: skin disorder therapeutics - Celtic Pharma

Alternative Names: IDEA-044; TDT-044

Latest Information Update: 01 Apr 2011

Price : $50

At a glance

  • Originator IDEA
  • Developer Celtic Pharma
  • Class Corticosteroids; Small molecules
  • Mechanism of Action Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Atopic dermatitis; Psoriasis

Most Recent Events

  • 01 Apr 2011 TDT 044 is still in preclinical trials for Psoriasis and Atopic dermatitis
  • 20 Jun 2008 Preclinical trials in Psoriasis (Topical)
  • 20 Jun 2008 Preclinical trials in Atopic dermatitis (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top